{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:38:49Z","timestamp":1777531129390,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.leukres.2019.04.015","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T11:02:19Z","timestamp":1556190139000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience"],"prefix":"10.1016","volume":"81","author":[{"given":"Michaela","family":"Spunarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Tom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Mraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvona","family":"Brychtova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Panovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Skuhrova Francova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Brzobohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Trbusek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"March 3","key":"10.1016\/j.leukres.2019.04.015_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"December 6","key":"10.1016\/j.leukres.2019.04.015_bib0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11899-018-0481-7","article-title":"Targeted therapies in CLL: monotherapy versus combination approaches","volume":"13","author":"Khan","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"January 1","key":"10.1016\/j.leukres.2019.04.015_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.leukres.2019.04.015_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11899-018-0438-x","article-title":"Frontline therapy of CLL: evolving treatment paradigm","volume":"13","author":"Boddy","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.015_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/asheducation-2018.1.242","article-title":"Selecting frontline therapy for CLL in 2018","volume":"30","author":"Jain","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"October 9747","key":"10.1016\/j.leukres.2019.04.015_bib0030","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet Lond Engl."},{"issue":"May 5","key":"10.1016\/j.leukres.2019.04.015_bib0035","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3324\/haematol.2014.115808","article-title":"Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience","volume":"100","author":"Herishanu","year":"2015","journal-title":"Haematologica"},{"issue":"July 7","key":"10.1016\/j.leukres.2019.04.015_bib0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"issue":"September 26","key":"10.1016\/j.leukres.2019.04.015_bib0045","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"September 9","key":"10.1016\/j.leukres.2019.04.015_bib0050","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/leu.2013.190","article-title":"Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab","volume":"27","author":"Fink","year":"2013","journal-title":"Leukemia"},{"issue":"October 16","key":"10.1016\/j.leukres.2019.04.015_bib0055","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"August 8","key":"10.1016\/j.leukres.2019.04.015_bib0060","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41375-018-0100-6","article-title":"Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab","volume":"32","author":"Gentile","year":"2018","journal-title":"Leukemia"},{"issue":"May 21","key":"10.1016\/j.leukres.2019.04.015_bib0065","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.015_bib0070","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/10428194.2017.1376746","volume":"59","author":"Appleby","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"September 5383","key":"10.1016\/j.leukres.2019.04.015_bib0075","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","article-title":"Enhanced phosphorylation of p53 by ATM in response to DNA damage","volume":"281","author":"Banin","year":"1998","journal-title":"Science"},{"issue":"October 7574","key":"10.1016\/j.leukres.2019.04.015_bib0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.leukres.2019.04.015_bib0085","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"December 26","key":"10.1016\/j.leukres.2019.04.015_bib0090","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med."},{"issue":"April 5","key":"10.1016\/j.leukres.2019.04.015_bib0095","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"July 7","key":"10.1016\/j.leukres.2019.04.015_bib0100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"issue":"December 12","key":"10.1016\/j.leukres.2019.04.015_bib0105","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat. Immunol."},{"issue":"Febuary 4","key":"10.1016\/j.leukres.2019.04.015_bib0110","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"July 7","key":"10.1016\/j.leukres.2019.04.015_bib0115","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.leukres.2013.03.018","article-title":"The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus","volume":"37","author":"Mraz","year":"2013","journal-title":"Leuk. Res."},{"issue":"June 25","key":"10.1016\/j.leukres.2019.04.015_bib0120","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"April 4","key":"10.1016\/j.leukres.2019.04.015_bib0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Malcikova","year":"2015","journal-title":"Leukemia"},{"issue":"April 14","key":"10.1016\/j.leukres.2019.04.015_bib0130","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood-2008-10-184853","article-title":"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens","volume":"113","author":"Lin","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2019.04.015_bib0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"60","key":"10.1016\/j.leukres.2019.04.015_bib0140","first-page":"154","article-title":"Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials","volume":"2016","author":"Gentile","year":"1990","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2019.04.015_bib0145","doi-asserted-by":"crossref","first-page":"e1000518","DOI":"10.1371\/journal.pbio.1000518","article-title":"Non-canonical NF-\u03baB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2","volume":"8","author":"Conze","year":"2010","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.leukres.2019.04.015_bib0150","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"1950","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.015_bib0155","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","article-title":"A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells","author":"Cun\u00ed","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2019.04.015_bib0160","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.leukres.2019.04.015_bib0165","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.leukres.2019.04.015_bib0170","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.015_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2014.06.003","article-title":"Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab","volume":"42","author":"Sebejova","year":"2014","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.04.015_bib0180","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/s41375-018-0211-0","article-title":"Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels","volume":"32","author":"Pavlasova","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2019.04.015_bib0185","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2019.04.015_bib0190","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2012-05-433540","article-title":"Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns","volume":"120","author":"Schuh","year":"2012","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:19Z","timestamp":1758934819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":38,"alternative-id":["S0145212619300797"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}